Shares of nano-cap company Petros Pharmaceuticals, Inc. (PTPI) more than doubled on Wednesday morning after the pharma company announced a 476% growth year-over-year of STENDRA tablet sales as part of an exclusive digital health marketing agreement with Hims & Hers Health, Inc.
The companies also announce the availability of additional dosages of STENDRA through the Hims & Hers platform, further expanding the partnership.
PTPI is currently trading at $3.5199, up $1.7699 or 101.1371%, on the Nasdaq, on a heavy volume of 134 million compared to average volume of 94 thousand shares.
Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.